Association between androgen deprivation therapy and excess mortality after covid-19 in patients with prostate cancer

Study type

• Study topic:
  Human medicinal product

  Disease /health condition
• Study type:
  Non-interventional study
• Scope of the study:
  Effectiveness study (incl. comparative)
• Data collection methods:
  Secondary data collection

Non-interventional study

• Non-interventional study design:
  Cohort

Study drug and medical condition

• Anatomical Therapeutic Chemical (ATC) code:
  100000096794

  bicalutamide

  100000096780

  Gonadotropin releasing hormone analogues

  100000096025

  Anti-gonadotropin-releasing hormones

  100000163806

  enzalutamide

  100000135905

  abiraterone
• Medical condition to be studied:
  COVID-19 treatment

  Prostate cancer metastatic

Population studied

• Short description of the study population:
  Men with prostate cancer were identified in The National Prostate Cancer Register (NPCR) of Sweden, which since 1998 captures 98% of all cases of prostate cancer in Sweden as compared to the Swedish Cancer Register to which registration is mandatory. ; In PCBaSe an open cohort was defined with men with prevalent prostate cancer alive on 1 March 2020 and similar subsets for corresponding months in 2015–2019. Men from three regions in which GnRH agonists were provided directly from the hospital without prescription were excluded.
• Age groups:
  Adults (18 to < 46 years)

  Adults (46 to < 65 years)

  Adults (65 to < 75 years)

  Adults (75 to < 85 years)

  Adults (85 years and over)
• Special population of interest:
  Other
• Special population of interest, other:
  Prostate cancer patients
• Estimated number of subjects:
  720000

Study design details

• Main study objective:
  The aim of this study was to estimate the impact of ADT on excess mortality in men with prostate cancer during the initial peak of covid-19 in the spring of 2020 compared to previous years.
• Data analysis plan:
  In order to avoid misclassification of cause of death, we will also compare excess mortality among men on ADT vs. men not on ADT regardless of cause of death. By use of Poisson regression we will compare the number of deaths during the pandemic with number of deaths in corresponding time periods in the previous five years. We will take Pca risk category, age, and comorbidity into account.

Documents

Study results

Gedeborg 2021 PLOS Excess mortality

Study publications

Gedeborg R, Styrke J, Loeb S, Garmo H, Stattin P (2021) Androgen deprivation th…